Estrogen therapy in gynecological cancer survivors

@article{Guidozzi2013EstrogenTI,
  title={Estrogen therapy in gynecological cancer survivors},
  author={Franco Guidozzi},
  journal={Climacteric},
  year={2013},
  volume={16},
  pages={611 - 617}
}
  • F. Guidozzi
  • Published 15 November 2013
  • Medicine
  • Climacteric
Abstract Treatment of gynecological cancer has significant impact on a woman's quality of life because it commonly includes removal of the uterus and ovaries, both being the core of a woman's femininity, whilst irradiation and chemotherapy, be they as primary therapy or when indicated as postoperative adjuvant therapy, will lead to ablation of ovarian function if the ovaries had not been removed. This will lead to an acute onset of menopausal symptoms, which may be more debilitating than those… 
Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy.
TLDR
The role of hormone therapy in menopausal patients with breast cancer and gynecologic malignancies is reviewed to determine whether it is considered safe in low-risk cancers but should be avoided in high-risk subtypes.
Treatment of climacteric symptoms in survivors of gynaecological cancer.
TLDR
For women treated for non-hormone-related tumours alternative treatments for menopausal symptoms should be given due consideration, as any reluctance to prescribe HRT for them has neither a biological nor a clinical basis.
Hormone replacement therapy in cancer survivors: Utopia?
TLDR
It is believed that with strong informed consent doctors may individually consider to prescribe some course of HRT in order to minimize menopausal symptoms and disease related to hormonal reduction.
The Role of Hormone Replacement Therapy in the Treatment of Menopausal Symptoms in Patients Diagnosed with Gynecologic Cancer
  • H. Çılgın
  • Medicine
    Hormone Therapy and Replacement in Cancer and Aging-related Diseases
  • 2020
TLDR
HRT does not appear to be associated with an increased risk of relapse in ovarian and endometrial cancer survivors, especially when used for a short period of time.
Management of Induced Menopause in Gynaecological Cancers and Their Challenges
TLDR
Current scientific data suggest that recurrence rates and survival are comparable between HRT users and non-users, and given the lack of evidence on the impact of HRT on recurrence and disease-free survival in survivors of cervical cancers, it would seem perfectly reasonable to prescribe HRT, particularly if they are premenopausal.
Hormone Replacement Therapy in Cancer Survivors – Review of the Literature
TLDR
This work reviews the latest evidence from in vitro experiments to clinical studies, regarding HRT in survivors of gynecologic and non-gynecologic cancers and group tumours regarding the oncologic risk of properly chosen female hormone replacement therapy in cancer survivors.
Hormone replacement therapy after surgery for epithelial ovarian cancer.
TLDR
Meta-analysis of these studies showed that HRT may improve overall survival and progression-free survival, and very low for quality-of-life assessment, incidence of breast cancer, transient ischaemic attack (TIA), cerebrovascular accident (CVA) and myocardial infarction (MI).
Management of Genitourinary Syndrome of Menopause in Female Cancer Patients: A Focus on Vaginal Hormonal Therapy.
TLDR
Tailored patient treatments include nonhormonal therapies (vaginal moisturizers, lubricants, pelvic floor physical therapy, dilator therapy, counseling), systemic and local hormonal therapies, and management variations noted depending on cancer type and characteristics.
Hormone replacement therapy for a young woman with cervical sarcomatoid squamous cell carcinoma
Cervical sarcomatoid squamous cell carcinoma (SSCC) is an extremely rare malignancy. We report the case of a young woman with cervical SSCC who experienced peri-menopausal syndrome following
Hormones and risk of breast and gynecological cancer
TLDR
Oral contraception increases breast cancer risk but is protective against ovarian and endometrial cancers and the influence of ovarian hyperstimulation has been controversially discussed and no clear association with these hormone-dependent tumors has been observed.
...
1
2
3
4
...

References

SHOWING 1-10 OF 83 REFERENCES
Hormone replacement therapy in gynecologic cancer survivors: why not?
TLDR
In select women, it is reasonable to discuss and offer conventional HRT for the amelioration of menopausal symptoms and to improve quality of life.
Managing menopausal symptoms after gynecological cancer
TLDR
There is no evidence showing hormones negatively influence survival after treatment for epithelial ovarian, squamous cervical or vulvar cancer, and it is reasonable to prescribe hormonal replacement therapy to symptomatic, well informed patients.
Hormone replacement after gynaecological cancer.
TLDR
As maintaining quality of life and minimising the physical and psychological impact of treatment side effects is one of the most important factors in cancer care, it is imperative to give patients unbiased information about their individual cancer which in most cases will allow them to use HRT without any detrimental effect on their survival.
Hormone replacement therapy in cancer survivors.
TLDR
There is no biological evidence that HRT may increase recurrence risk and the reticence to prescribe HRT in women previously treated for other non hormone-related tumours has neither a biological nor a clinical basis.
Menopause, hormone replacement and gynaecological cancers
TLDR
No study to date has found HRT to have a detrimental effect on survival in patients with early stage endometrial cancer, epithelial ovarian cancer, cervical cancer and vulval tumours, and HRT is only an absolute contraindication in low-grade endometricrial stromal sarcomas and is best avoided in granulosa cell ovarian tumours.
Hormone replacement therapy in women treated for gynaecological malignancy.
TLDR
Re-evaluation of the current view that HRT should no be given to women treated for a gynaecological malignancy is strongly warranted after evaluating the advantages and the disadvantages of HRT use in each individual patient.
Safety of hormone replacement therapy in gynaecological cancer survivors
TLDR
Gynaecological cancer survivors using HRT, although they seem to have little if any risk for recurrence, should be correctly informed about the lack of strong evidence.
Estrogen replacement therapy in the patient treated for endometrial cancer
TLDR
The history of endometrial cancer does not appear to be a contraindication to hormone replacement therapy in patients with stage I disease, and the estrogen group experiencing longer disease-free survival.
Hormonal therapy in gynecological sarcomas
TLDR
A critical appraisal of the existing data regarding hormonal manipulation in uterine sarcomas is included and attempts to make recommendations for endocrine treatments in specific settings, as well as suggest targets/medications for future research.
Hormonal replacement therapy in ovarian cancer survivors: a survey among Greek gynecologists.
TLDR
One out of two Greek gynecologists would prescribe HRT in ovarian cancer survivors, and an alternative therapy, mainly CNS medications, would be suggested by 21% of the opposers.
...
1
2
3
4
5
...